OUR MISSION
TECHNOLOGY
PRODUCTS
Offerings
Platform
ABOUT US
Data Partners
Publications
Our Team
Careers
News & Updates
CONTACT
Nucleai is Leading the Spatial Biology Revolution in Precision Medicine
Transforming Precision Medicine Powered by AI-Pathology
Scroll For More
Our Mission
We are committed to bringing the power of spatial biology to reality by providing pharmaceutical companies and clinicians with AI-powered image analysis applications. Our platform enhances drug development, supports treatment decisions and improves patient lives.
Technology
Our image analysis and biomarker discovery technology leverages real-world pathology, clinical and molecular datasets to better understand cancer biology, optimize patient stratification and improve patient care.
MILLIONS
Of Annotated Cells
12
Cancer Indications
50+
Data Partners
Initializing
Gaining access to millions of annotated cells across 10+ cancer indications.
Analyzing pathology slides
Our algorithms detect and characterize tissue and cell architecture.
Calculating Features
Cell & area locations are intersected to compute over hundreds of complex feature values.
Predicting Response
Deep-learning models combining spatial features and clinical data drive the discovery of pathology-based spatial biomarkers.
PRODUCTS
Our Offering
Exploratory Research Platform
Our Platform empowers researchers to discover novel, human interpretable pathology-based biomarkers that predict response to therapy, identify genomic markers or explain complex biological phenomena at scale.
AI-Powered Clinical Trial Assays
Qualified biomarkers are incorporated into prospective clinical trials via Nucleai's AI-powered digital assays. In partnership with CROs and central laboratories, we support a compliant (FDA, CLIA, GxP) and scalable patient selection process.
Companion Diagnostics Development
In partnership with biopharma, diagnostics and clinical laboratories, we develop and deploy Nucleai's digital assays as companion diagnostics across the world, providing physicians with the best diagnostic tools to improve patient lives.
Our Platform
Nucleai’s platform unlocks spatial insights. In Nucleai Atom, your pathology slides are transformed into raw data of cell and area locations. The raw data is fed into the Nucleai engine, computing hundreds of spatial features intersected with outcome to predict drug response.
ABOUT US
We are transforming precision medicine with AI-powered pathology
Our team’s work is a unique collaboration of experienced AI technologists, physicians and exceptional healthcare research professionals.
DATA & INSTITUTIONAL PARTNERS
SCIENTIFIC PUBLICATIONS
ASCO 2021
Predicting Response to Pembrolizumab in NSCLC Using AI-pathology
Learn More
ASCO 2020
Predictive Potential of Lymphocyte Spatial Signatures In Breast Cancer Patients
Learn More
USCAP 2019
Identification of Helicobacter pylori Organisms by Digital Image Analysis
Learn More
USCAP 2019
AI-Based Digital Image Analysis for Pathological Categorization of Colonic Polyps
Learn More
LEADERSHIP
ADVISORS
Stanley Robboy
M.D, Ph.D
Alex Lazar
M.D, Ph.D.
Hossein Borghaei
M.D
Klaas Zuideveld
Ph.D.
Luba Greenwood
Ph.D
CAREERS
Join Us in Biomarker Discovery
At Nucleai, we bring physicians and researchers cutting edge AI-based technology that identifies pathology-based biomarkers that can predict response to therapy and significantly improve patient outcomes. Come join our team of experienced AI engineers, world renowned clinicians, and others, to revolutionize precision medicine and make a major impact.
NEWS & UPDATES
Nucleai and Jefferson Health Launch a Strategic Collaboration to Discover Novel Spatial Immunotherapy Biomarkers Utilizing Nucleai’s Spatial Biology Platform
Nucleai, a leader in AI-powered spatial biology, and Jefferson Health, a leading cancer center, announce that they have entered into a strategic collaboration to discover spatial immunotherapy biomarkers, leveraging Nucleai’s ATOM platform and Jefferson’s repository of pathology and clinical data. The mutual collaboration will help advance AI-based solutions in discovering histological biomarkers and patient selection in clinical trials and clinical settings. The Israeli Innovation Authority supports the collaboration as part of the International Health-Tech Pilot Program.
Nucleai and Merck KGaA Launch Translational Medicine Collaboration
Nucleai and Merck KGaA Darmstadt Germany announced a long-term collaboration to leverage Nucleai's image analysis and biomarker discovery platform
Israeli AI firm Nucleai, Sheba launch partnership for data collaboration
Sheba and Nucleai are working to advance the study of technological and AI-based solutions to aid in the discovery of histological biomarkers.
Nucleai and Debiopharm Launch Research Collaboration Utilizing Nucleai's Ai-Powered Biomarker Platform
Nucleai's pathology-based platform analyzes tissue images using computer vision and machine learning methods to model the tumor and the immune system's spatial characteristics, creating unique and specific histological biomarkers that can predict patient response.
VISIT US
1375 W Fulton Ave, Chicago, IL 60607, US Suite 650
121 Menachem Begin, 59th floor, Tel Aviv, Israel
Schedule a meeting
Privacy Policy
Terms & Conditions
©2021. All rights reserved Nucleai, Inc.